Abstract Number: 521 • 2019 ACR/ARP Annual Meeting
Discontinuation of Disease Modifying Drugs Due to Inefficacy in Patients with Incident Rheumatoid Arthritis
Background/Purpose: The treatment of Rheumatoid Arthritis (RA) has undergone a big change in the last two decades with the Disease Modifying Drugs (DMARDs). These drugs…Abstract Number: 2376 • 2019 ACR/ARP Annual Meeting
Modifiable Factors Associated with Response to Treatment in Early Rheumatoid Arthritis
Background/Purpose: Among the potentially modifiable prognostic factors in RA, there is evidence for associations with smoking history, BMI and dietary fish oil supplementation. An integrated…Abstract Number: 107 • 2019 ACR/ARP Annual Meeting
Expanded Peripheral T Helper Cells Characterize the Early Rheumatoid Arthritis Synovium
Background/Purpose: Programmed cell death protein 1 (PD-1) expressing T-cells are implicated in the pathogenesis of autoimmune inflammatory diseases such as rheumatoid arthritis (RA). In secondary…Abstract Number: 1182 • 2019 ACR/ARP Annual Meeting
Fluorescence Optical Imaging in the Diagnosis of Individuals Suspected of Arthritis Development – a Probabilistic Approach
Background/Purpose: Among the arsenal of available techniques for arthritis prediction and diagnosis, fluorescence optical imaging (FOI) has shown to be useful in detecting clinically manifest…Abstract Number: 2387 • 2019 ACR/ARP Annual Meeting
Management of Patients with Incident Rheumatoid Arthritis in Rheumatology Clinical Practice
Background/Purpose: Treatment of Rheumatoid Arthritis (RA) has changed drastically in the last two decades in strategies and objectives, as well as in therapeutic options, especially…Abstract Number: 179 • 2019 ACR/ARP Annual Meeting
The Burden of Comorbidity in Patients with RA, PSA or SPA in a General Practice Registry
Background/Purpose: Rheumatoid arthritis (RA), psoriatic arthritis (PSA) and spondyloarthritis (SPA) are the most common inflammatory rheumatic diseases, associated with a high burden of comorbidities and…Abstract Number: 1205 • 2019 ACR/ARP Annual Meeting
Real-World Remission Outcomes in the First Year Following RA Diagnosis Vary Considerably with the Disease Activity Index Used and a Sizable Proportion Have Persistent Active Disease Across All Measures: Results from the Canadian Early Arthritis Cohort (CATCH)
Background/Purpose: Early RA diagnosis and initiation of DMARDs following a treat-to -target approach is recommended to optimize remission outcomes. Several RA disease activity indices are…Abstract Number: 2395 • 2019 ACR/ARP Annual Meeting
DMARD-naïve Rheumatoid Arthritis (RA) Patients Have Greater RAPID3 Improvement over 6 Months After 1st Visit Than Patients Who Were Treated Previously Treated with DMARDs, Although Baseline RAPID3 Was Similar: The Importance of Early Treatment
Background/Purpose: A study of patients with RA at their first visit to an academic rheumatology site indicated an unexpected observation that 75% of patients had…Abstract Number: 198 • 2019 ACR/ARP Annual Meeting
Assessing Care Quality in Rheumatology Services
Background/Purpose: There is high-quality evidence that prompt diagnosis and treatment have beneficial impact on outcomes in RA. Current guidelines from both North America and Europe…Abstract Number: 1340 • 2019 ACR/ARP Annual Meeting
Patterns of Sustained Remission and Subsequent DMARD Tapering in Early Rheumatoid Arthritis: Data from the Canadian Early Arthritis Cohort
Background/Purpose: Rheumatoid arthritis (RA) treatment emphasizes aggressive titration of disease-modifying antirheumatic drugs (DMARDs) with the goal of achieving disease remission. This often includes the use…Abstract Number: 2818 • 2019 ACR/ARP Annual Meeting
Differences in the Phenotypic Landscape and Antigen Specificity of CD4+ T Cells Are Present in CCP+ Subjects Before the Onset of Rheumatoid Arthritis
Background/Purpose: The “Targeting Immune Responses for Prevention of RA” (TIP-RA) collaboration studies individuals at high risk for developing rheumatoid arthritis (RA) because of serum anti-citrullinated…Abstract Number: 1483 • 2018 ACR/ARHP Annual Meeting
Comparison of Clinical Features of Seronegative and Seropositive Early Rheumatoid Arthritis: Blinded Data from the Ongoing Phase IIb Trial with the EP4 Receptor Antagonist CR6086 in DMARD-Naïve Patients
Background/Purpose: Rheumatoid arthritis patients positive for rheumatoid factor (RF) or anti-cyclic citrullinated peptide antibody (ACPA) are considered to manifest an aggressive disease course compared with…Abstract Number: 1485 • 2018 ACR/ARHP Annual Meeting
Survivin Measurements Improve Prediction of Rheumatoid Arthritis Among Patients with Unexplained Arthralgia
Background/Purpose: Early recognition of rheumatoid arthritis (RA) is believed to be the key to successful treatment of this disease. Symptoms of arthralgia often predate development…Abstract Number: 1486 • 2018 ACR/ARHP Annual Meeting
Incidence of Subclinical Signs of Inflammation in Patients with New Onset of Non-Specific Musculoskeletal Symptoms and Anti-Citrullinated Peptide Positivity: First Interims Analysis of the Panora Trial
Background/Purpose: Rheumatoid Arthritis (RA) is a chronic inflammatory joint disease affecting approx. 1% of the adult population of Northern Europe and North America. Strategies for…Abstract Number: 1488 • 2018 ACR/ARHP Annual Meeting
Identification of Joint Locations That Are Poor Prognostic in an Early Seropositive Erosive RA Cohort
Background/Purpose: Patients (pts) with early RA often present with multiple and different areas of joint involvement. While the ACR and EULAR guidelines specify high disease…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 18
- Next Page »